H.C. Wainwright lowered the firm’s price target on Vigil Neuroscience to $17 from $24 and keeps a Buy rating on the shares. The company announced its intention not to conduct the interim analyses, following a Type C meeting with the FDA, where the FDA has shown willingness for a potential accelerated approval pathway, the analyst tells investors in a research note. The firm thinks it is prudent to wait for the full and mature 12-month data, saying Vigil might have robust biomarker data that supports iluzanebart’s reasonable likelihood to predict clinical benefit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer’s Association International Conference
- Vigil Neuroscience Advances IGNITE Trial, Eyes Accelerated Approval
- Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
- Vigil Neuroscience price target raised to $23 from $22 at Wedbush
- Sanofi investing $400M in Vigil Neuroscience, says Guggenheim